GlaxoSmithKline: EU approves new COPD drug.
(CercleFinance.com) - GlaxoSmithKline has said that the European Commission has granted marketing authorisation for Trelegy Ellipta as a maintenance treatment for moderate-to-severe chronic obstructive pulmonary disease (COPD).
Brussels' decision only concerns adult patients who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
Developed with US-based Innoviva, Trelegy Ellipta is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA), delivered once daily in GSK's Ellipta dry powder inhaler.
It is due to be launched in Europe by the end of the year.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Brussels' decision only concerns adult patients who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
Developed with US-based Innoviva, Trelegy Ellipta is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA), delivered once daily in GSK's Ellipta dry powder inhaler.
It is due to be launched in Europe by the end of the year.
Copyright (c) 2017 CercleFinance.com. All rights reserved.